Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, gives an overview of the background and results from a study that analyzed perioperative MRI and recurrence rates in women with DCIS.
Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, gives an overview of the background and results from a study that analyzed perioperative MRI and recurrence rates in women with DCIS.
This large retrospective study was done to evaluate the association of MRI and long-term outcomes, meaning locoregional recurrence and contralateral breast cancer in women with DCIS. Researchers found that there was no difference between the rates of locoregional recurrence and those women with or without a perioperative MRI at 5 and 8 years. There was also no significant difference observed in the rates of locoregional recurrence at 5 or 8 years in women who did not have radiation therapy, though theoretically these patients would benefit most from the addition of MRI. There was also no difference in the rates of contralateral breast cancer between women with and without MRI.
Ultimately, Pilewskie says, these data add to the literature that MRI use for women with DCIS is not associated with improved outcomes.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More